SOMERSET, N.J., June 28, 2021 – Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has been recognized by the Royal Society for the Prevention of Accidents (RoSPA) for demonstrating high health and safety standards.
Catalent received the gold Health and Safety Award for working hard to provide a safe, healthy and inclusive working environment for its staff, customers and contractors. This is the third consecutive year that Catalent…
NOTTINGHAM, UK – 29 June, 2021 – Life Science Newswire – Sygnature Discovery, the leading provider of integrated drug discovery services, has received a significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co. Financial details have not been disclosed.Sygnature is a world-class provider of outsourced drug discovery services to leading pharma and biotech companies. The business operates from two state-of-the-art science facilities in the UK, at BioCity in Nottingham and Alderley Park in Cheshire, employing over 450…
Cambridge, UK,– 29 June 2021: IONTAS Limited (IONTAS), a leader in the discovery and optimization of fully human antibodies, today announces that F-star Therapeutics, Inc. (NASDAQ: FSTX), has dosed the first patients in a Phase 1 clinical trial, with FS222, a CD137/PD-L1 bispecific antibody.
IONTAS applied its proprietary technology to generate a component utilized within FS222, which was subsequently licenced to F-star. The initiation of this trial adds to the growing portfolio of antibodies generated by IONTAS that are entering clinical trials.
António Parada, CEO at IONTAS, commented: “We…
Cambridge and London, UK, 29 June 2021: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single and multi-organ microphysiological systems (MPS), today announced that King’s College London, an internationally renowned research university, has adopted the PhysioMimix™ Multi-Organ MPS. Following a successful research collaboration, King’s College London selected the system to create a unique human-relevant liver-intestinal model for characterizing and manipulating host-microbial interactions, to support improved outcomes in cirrhosis. Launched in March 20211, CN Bio…
We are now recruiting mentors for the sixth round of our Patient Group Mentoring Programme!
If you believe that you have something to offer to a rare disease patient group, whether that be advice on time management, ideas for patient involvement in research or simply a listening ear, we want to hear from you!
The deadline to apply is no later than midnight on 4th July - AKA this Sunday!
Our 2021-22 Programme will officially launch on 14th July.
To learn more and apply as a mentor: https://www.findacure.org.uk/patient-group-mentoring-programme-2021-22/
We particularly welcome individuals with…
Dr. Kazuo Takayama from the renowned Center for iPS Cell Research and application (CiRA) at Kyoto University (Japan) has given a unique insight into his pioneering research that has successfully modelled the SARS-CoV-2 life cycle in undifferentiated iPSCs - which were previously uninfectable.The presentation which was given at ISSCR 2021, the leading professional organization for stem cell scientists, discussed how iPSCs and organoids can be used in COVID-19 drug discovery research.This innovation showcase presentation at ISCCR 2021 was sponsored by…
22 June 2021
Taylor Wessing expands offering in China with the launch of Beijing Tailun IP Agency
Today we are announcing our expansion with the launch of an exclusive relationship with a specialist trade mark and IP agency in China.
With international law firms restricted from practicing Chinese law, a distinct legal entity has been established and permitted to provide a range of intellectual property related services by Chinese regulators.
Beijing Tailun IP Agency opened at the start of 2020 to pilot operations with selected Taylor Wessing clients before its official launch this week, and…
LINK Medical and Ectin Research AB have signed an agreement appointing LINK Medical Research AB to run the Phase I/II clinical study of the treatment of metastatic bladder cancer patients with the drug candidate MFA-370. Ectin Research aims to submit its clinical trial application (CTA) to the Swedish Medical Products Agency, in collaboration with LINK Medical, followed by additional regulatory applications in two other countries.
Bladder cancer is one of the most aggressive cancers; 50-70% of tumours recur and 10-20% become metastatic. Current treatments of metastatic bladder cancer…
Biocair recently opened a new office in Chicago, bringing the total number of US offices to nine. This addition to Biocair’s global network is just one of several investments made in the last year, all part of the company’s efforts to further expand its industry-leading supply chain solutions for life sciences.
The new facility will accommodate certified packaging and conditioning areas for a wide range of temperatures, including an advanced liquid nitrogen service station, as well as office space for Operations staff.
June Rivera, Operations Development Director at Biocair, said:
“…